Avadel Pharmaceuticals plc announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in the following upcoming investor conferences: Piper Sandler 33rd Annual Virtual Healthcare Conference: Participation starting on Monday, November 29.
DUBLIN, Ireland, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Avadel Pharma (Flamel Technologies S.A. Acquired Avadel) (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in the following upcoming investor conferences:
- Piper Sandler 33rd Annual Virtual Healthcare Conference: Participation starting on Monday, November 29 with a Fireside chat available for on-demand viewing starting today, Monday, November 22 at 10:00 a.m. ET.
- Evercore ISI 4th Annual HealthCONx Conference: Fireside chat on Wednesday, December 1 at 2:00 p.m. E.T.
A webcast of these events, as well as archived recordings, will be available on Avadel’s Investor Relations website, investors.avadel.com, for 90 days following each conference.
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Our current lead drug candidate, FT218, is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. For more information, please visit www.avadel.com.
Investor Contact:
Courtney Turiano
Stern Investor Relations, Inc.
Courtney.Turiano@sternir.com
(212) 698-8687
Media Contact:
Nicole Raisch Goelz
Real Chemistry
ngoelz@realchemistry.com
(408) 568-4292
